1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,770 | 0,785 | 11:54 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| Mi | ABBISKO-B: ABSK061 for Achondroplasia Treatment Granted Orphan Drug Designation by EMA | 1 | AASTOCKS | ||
| Mi | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS' LAVENGRATINIB (ABSK061) FOR THE TREATMENT OF ACHONDROPLASIA GRANTED ORPHAN DESIGNATION ... | 1 | HKEx | ||
| 14.10. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 02.10. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 1 | HKEx | ||
| 24.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| ABBISKO CAYMAN Aktie jetzt für 0€ handeln | |||||
| 22.09. | ABBISKO-B (02256): 2026 INTERIM REPORT | 1 | HKEx | ||
| 21.09. | Abbisko's Lavengratinib Shows Early Height-Growth Benefit In Phase II Achondroplasia Study | 1 | RTTNews | ||
| 21.09. | Abbisko Therapeutics Announces Positive Preliminary Phase 2 Results with Lavengratinib (ABSK061) for the Treatment of Achondroplasia | 174 | PR Newswire | SHANGHAI, Sept. 20, 2026 /PRNewswire/ -- 21 September 2026 (Beijing time), Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK)... ► Artikel lesen | |
| 21.09. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS ANNOUNCES POSITIVE PRELIMINARY PHASE II RESULTS WITH LAVENGRATINIB (ABSK061) FOR THE ... | 1 | HKEx | ||
| 17.09. | ABBISKO-B (02256): POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON SEPTEMBER 17, 2026 | - | HKEx | ||
| 16.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 01.09. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 31.08. | ABBISKO-B (02256): VOLUNTARY ANNOUNCEMENT - ABBISKO THERAPEUTICS COMPLETES FIRST PATIENT DOSING IN PHASE I CLINICAL TRIAL OF NOVEL PAN-KRAS INHIBITOR ... | 1 | HKEx | ||
| 28.08. | ABBISKO-B (02256): NOTICE OF EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 28.08. | ABBISKO-B (02256): PROXY FORM FOR EXTRAORDINARY GENERAL MEETING | 2 | HKEx | ||
| 28.08. | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME AND NOTICE OF EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 25.08. | ABBISKO-B (02256): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 24.08. | ABBISKO-B (02256): PROPOSED CHANGE OF COMPANY NAME | 1 | HKEx |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TANGO THERAPEUTICS | 27,950 | +0,07 % | Tango Therapeutics (TNGX) Has Striking Pancreatic Cancer Data. How Much Is Priced In? | ||
| VERA THERAPEUTICS | 29,050 | 0,00 % | Vera Therapeutics plans FDA filing for IgAN drug in Q4 2026 | ||
| NURIX THERAPEUTICS | 25,510 | 0,00 % | H.C. Wainwright raises Nurix stock price target on strong revenue | ||
| KINIKSA PHARMACEUTICALS | 80,79 | 0,00 % | AstraZeneca, Cardiol Therapeutics, Kiniksa - Neue Hoffnung für Herzpatienten | Herz-Kreislauf-Erkrankungen gehören weltweit zu den größten medizinischen Herausforderungen. Während etablierte Pharmakonzerne Milliarden in neue Wirkstoffe und Künstliche Intelligenz investieren, entwickeln... ► Artikel lesen | |
| HARMONY BIOSCIENCES | 36,040 | +0,03 % | Harmony Biosciences drops amid court hearing on Wakix patent | ||
| QIAGEN | 44,995 | +0,13 % | Börsenschluss: Sell on Good News - Qiagen springt, AI-Werte brechen ein | Gute Zahlen, fallende Kurse: Am Donnerstag dominierten an der Börse Frankfurt Gewinnmitnahmen. Selbst überzeugende Quartalsberichte lockten kaum noch Käufer an - das Muster "Sell on Good News" setzte... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,950 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 32,200 | 0,00 % | Arcutis BioTherapeutics advances 11% to new 52-week high | ||
| SUMMIT THERAPEUTICS | 15,555 | +0,03 % | Akeso, Inc.: Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer | Becomes the 7th International Registrational Clinical Trial for Ivonescimab
Clinical Trial Site Activations in the United States Expected to Begin Q4 2026
HONG... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 12,340 | 0,00 % | What's Going On with MoonLake Immunotherapeutics Stock on Thursday? | ||
| RAPPORT THERAPEUTICS | 26,530 | 0,00 % | Jones Trading raises Rapport Therapeutics price target on pipeline potential | ||
| IMMUNOME | 18,260 | 0,00 % | William Blair initiates Immunome stock coverage with outperform rating | ||
| ARCUS BIOSCIENCES | 19,320 | -0,16 % | Arcus Biosciences prices $250M public offering at $17.50 per share | ||
| RECURSION PHARMACEUTICALS | 3,580 | 0,00 % | Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast | ||
| ABSCI | 9,370 | 0,00 % | Absci Corporation: Absci Announces Preliminary Details for Phase 2 STORYLINE Trial of AI-Designed Antibody ABS-201 for Endometriosis | Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial... ► Artikel lesen |
Das Unternehmen ABBISKO CAYMAN LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,785 Euro und damit -0,63 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABBISKO CAYMAN LTD finden Sie auf Wallstreet Online.